Cargando…

Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I–III pancreatic ductal adenocarcinoma: a retrospective cohort study

Neoadjuvant therapy remains controversial in treating resectable pancreatic ductal adenocarcinoma (PDAC) patients. This study aims to assess the impact of neoadjuvant therapy on survival in patients with PDAC according to their clinical stage. METHODS: Patients with resected clinical Stage I–III PDA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Yiping, Gao, Song, Yu, Xin, Zhou, Tianxing, Xie, Yongjie, Guo, Xiaofan, An, Ran, Wang, Xiuchao, Zhao, Tiansuo, Chang, Antao, Gao, Chuntao, Yu, Jun, Hao, Jihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389558/ https://www.ncbi.nlm.nih.gov/pubmed/37132194 http://dx.doi.org/10.1097/JS9.0000000000000425

Ejemplares similares

Serum insulin‐like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinoma‐associated malnutrition and muscle wasting
por: Dong, Jie, et al.
Publicado: (2021)

SCF, Regulated by HIF-1α, Promotes Pancreatic Ductal Adenocarcinoma Cell Progression
por: Gao, Chuntao, et al.
Publicado: (2015)

Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma
por: Li, Xiaojie, et al.
Publicado: (2020)

An invited commentary on ‘Survival outcomes of neoadjuvant therapy followed by radical resection versus upfront surgery for stage I-III pancreatic ductal adenocarcinoma: a retrospective cohort study’
por: Coppola, Alessandro, et al.
Publicado: (2023)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Tumoral EHF predicts the efficacy of anti-PD1 therapy in pancreatic ductal adenocarcinoma
por: Liu, Jing, et al.
Publicado: (2019)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
por: Li, Haorui, et al.
Publicado: (2023)

Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis
por: Ratnayake, Bathiya, et al.
Publicado: (2020)

Perioperative Serum Scoring Systems Predict Early Recurrence and Poor Prognosis of Resectable Pancreatic Cancer
por: Li, Shengnan, et al.
Publicado: (2022)

Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression
por: Huang, Chongbiao, et al.
Publicado: (2017)

Hypoxia-Inducible Factor-1α Regulates Chemotactic Migration of Pancreatic Ductal Adenocarcinoma Cells through Directly Transactivating the CX3CR1 Gene
por: Zhao, Tiansuo, et al.
Publicado: (2012)

Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2014)

Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
por: Zhao, Tiansuo, et al.
Publicado: (2019)

CypA, a Gene Downstream of HIF-1α, Promotes the Development of PDAC
por: Zhang, Huan, et al.
Publicado: (2014)

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma
por: Fu, Danqi, et al.
Publicado: (2023)

Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes
por: Wang, Xiuchao, et al.
Publicado: (2016)

Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for pancreatic ductal adenocarcinoma: A retrospective study
por: He, Yong-Gang, et al.
Publicado: (2022)

Efficacy of upfront hepatectomy without neoadjuvant chemotherapy for resectable colorectal liver metastasis
por: Ono, Kosuke, et al.
Publicado: (2021)

Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma
por: Nappo, Gennaro, et al.
Publicado: (2023)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Preoperative ultrasound combined with routine blood tests in predicting the malignant risk of pancreatic cystic neoplasms
por: Wang, Xiuchao, et al.
Publicado: (2022)

The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer: a cross sectional study
por: Su, Yung-Yeh, et al.
Publicado: (2023)

ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour–stromal IL-1β/NF–κB/ESE3 signalling axis
por: Zhao, Tiansuo, et al.
Publicado: (2022)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

A neoadjuvant therapy compatible prognostic staging for resected pancreatic ductal adenocarcinoma
por: Zhu, Lingyu, et al.
Publicado: (2023)

Combination of RUNX1 inhibitor and gemcitabine mitigates chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress
por: She, Chunhua, et al.
Publicado: (2023)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
por: Ei, Shigenori, et al.
Publicado: (2023)

Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
por: Ren, Xiaohan, et al.
Publicado: (2019)

Neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic cancer: A Markov decision analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
por: Jeon, Hyun Jeong, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical trials
por: Ghanem, I., et al.
Publicado: (2022)

Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
por: Zhou, Tianxing, et al.
Publicado: (2023)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Adjuvant therapy in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and radical resection in pathological stages I–III
por: Lino-Silva, Leonardo S., et al.
Publicado: (2020)

Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis
por: Bradley, Alison, et al.
Publicado: (2019)

Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis
por: Chen, Xing, et al.
Publicado: (2017)

Increased SPARC expression is associated with neoadjuvant therapy in resectable pancreatic ductal adenocarcinoma
por: Hartley, Christopher, et al.
Publicado: (2020)

Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research
por: Cloyd, Jordan M, et al.
Publicado: (2020)

Impact of radiologic splenic vessel invasion in resectable left-sided pancreatic ductal adenocarcinoma: predictor of early systemic recurrence following upfront surgery
por: Lee, Seung Jae, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qjmfsepitfe67l8dg9r7v8bcl7